Item 1.01 |
Entry into a Material Definitive Agreement. |
On May 14, 2024 (the “Amendment Effective Date”), Verrica Pharmaceuticals Inc. (the “Company”) entered into an amendment (the Amendment”) to the Collaboration and License Agreement (the “Collaboration and License Agreement”) dated March 17, 2021, by and between the Company and Torii Pharmaceutical Co., Ltd. (“Torii” and together with the Company, the “Parties”).
Pursuant to the Amendment, the Parties will equally split the cost of a global Phase 3 clinical trial of YCANTH (VP-102) for the treatment of common warts (the “Trial”), with Torii paying all of the costs when due and the Company repaying Torii half of the costs (the “Company Portion”) as further described below. The Company Portion accrues interest annually at the greater of (i) the one-month Secured Overnight Financing Rate plus 2% and (ii) 6%. Torii has the right to offset the Company Portion plus applicable interest against certain of the milestone-based payments that would otherwise be due to the Company under the terms of the Collaboration and License Agreement. In addition, if Torii has not received payment or other recoupment in full of the Company Portion plus applicable interest within 60 months after the date on which Torii made its first payment for the Trial costs, Torii may invoice the Company for the remained Company Portion plus applicable interest.
If the Trial cannot be conducted in Japan as a result of revocation of regulatory approval or the Company materially breaches either the Collaboration and License Agreement as amended by the Amendment (the “Agreement”) or the Warrant (as defined below) and such breach remains uncured for a specified period, Torii is not required to pay for any additional Trial costs and the Company will be required to repay Torii for all Trial costs incurred by Torii, but such repayment will not occur prior to a specified period of time following the expiration of the Company’s Credit Agreement with OrbiMed Royalty & Credit Opportunities IV, LP.
The Parties also agreed that if the Company licenses to a third party any of the data generated in connection with Trial (a “License”), the Parties will negotiate in good faith and enter into an agreement whereby the Company will pay Torii at least a low double-digit percentage of the consideration received by the Company under such License.
Pursuant to the Amendment, Torii has the right to terminate the Agreement upon specified prior written notice to the Company, but cannot terminate prior to the earlier of (i) the date of database lock for the Trial or (ii) termination of the Trial. The other termination provisions in the Collaboration and License Agreement remain unchanged.
The foregoing is a summary description of certain terms of the Amendment, is not complete and is qualified in its entirety by reference to the text of the Amendment, which the Company expects to file as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2024.
Item 3.02 |
Unregistered Sales of Equity Securities. |
On the Amendment Effective Date, in connection with the Torii Amendment, the Company issued Torii a warrant (the “Warrant”) to purchase up to 500,000 shares of the Company’s common stock (the “Exercise Shares”) at an exercise price per share of $9.56, which equaled the closing price of the Company’s common stock on the trading day before the Amendment Effective Date. The Warrant has a term of ten years (the “Term”) and is exercisable only with respect to the Exercise Shares that have vested as of the date of exercise. The Exercise Shares vest as set forth below:
|
• |
|
166,666 of the Exercise Shares will vest in full on the date during the Term that the first patient is dosed in the Trial. |
|
• |
|
166,666 of the Exercise Shares will vest in full on the date during the Term that the database lock for the Trial occurs. |
|
• |
|
166,668 of the Exercise Shares will vest in full on the date during the Term that the Company submits a New Drug Application (as more fully defined in 21 CFR 314.5, et seq.) with the U.S. Food and Drug Administration for YCANTH (VP-102) for the treatment of common warrants. |